Coronaviridae

ImmunoPrecise's PolyTope™ TATX-03 Antibody Cocktail Potently Neutralizes SARS-CoV-2 Delta Variant in in vitro Pseudovirus Assays

Retrieved on: 
Thursday, July 22, 2021
Biotechnology, General Health, Infectious diseases, Health, Clinical trials, Variants of SARS-CoV-2, Coronaviridae, SARS-CoV-2, SARS-CoV-2 lineage B.1.617, SARS-CoV-2 Delta variant, Severe acute respiratory syndrome coronavirus 2, SARS-CoV-2 Kappa variant, SARS-CoV-2 Alpha variant, SARS-CoV-2 Beta variant, Variant of concern

As such, the Company continuously validates, and has demonstrated to date, maintained neutralization potency of IPAs multi-antibody cocktail towards SARS-CoV-2 variants of concern.

Key Points: 
  • As such, the Company continuously validates, and has demonstrated to date, maintained neutralization potency of IPAs multi-antibody cocktail towards SARS-CoV-2 variants of concern.
  • IPA previously announced that TATX-03 demonstrated strong efficacy in reducing viral load in vivo using a hamster challenge model and potently neutralized pseudovirus of Alpha (B.1.1.7) and Beta (B.1.351) variants in vitro.
  • Additional evaluation of virus neutralization potency in an in vitro pseudovirus-based assay revealed that IPAs TATX-03 anti-SARS-CoV-2 antibody cocktail is also not affected by the rapidly spreading Delta variant (B.1.617.2).
  • Parallel reactivity screening of the individual antibodies of TATX-03 revealed differential susceptibility of the lead components towards the Delta (B.1.617.1) variant with the majority showing maintained binding.

eFFECTOR Therapeutics Doses First Patient with COVID-19 in Phase 1b Clinical Trial Evaluating Zotatifin as a Host-Targeted Antiviral Agent

Retrieved on: 
Thursday, July 22, 2021
Coronaviridae, Zoonoses, Animal diseases, Sarbecovirus, Antiviral drugs, Human coronavirus 229E, Severe acute respiratory syndrome coronavirus 2, Coronavirus, Coronavir, COVID-19, Middle East respiratory syndrome–related coronavirus, Severe acute respiratory syndrome coronavirus

The Phase 1b trial is a double-blind, randomized dose escalation trial in non-hospitalized patients ages 18-65 with mild to moderate COVID-19.

Key Points: 
  • The Phase 1b trial is a double-blind, randomized dose escalation trial in non-hospitalized patients ages 18-65 with mild to moderate COVID-19.
  • Further, in vitro studies have shown that zotatifin has potent antiviral activity across all unique coronavirus subtypes tested, including SARS-CoV-2, SARS-CoV-1, MERS-CoV and CoV-229E.
  • Zotatifin, eFFECTORs inhibitor of eIF4A, has recently completed the dose-escalation portion of a Phase 1/2 trial, and is now progressing into Phase 2a indication-specific expansion cohorts.
  • Neither LWAC nor eFFECTOR gives any assurance that either LWAC or eFFECTOR or the combined company will achieve its expectations.

Delta Variant Testing Device Developed by UAT Group Affiliate, Bacter Scientific

Retrieved on: 
Thursday, July 22, 2021
Coronaviridae, Sarbecovirus, Variants of SARS-CoV-2, COVID-19, Severe acute respiratory syndrome coronavirus 2, Zoonoses, Severe acute respiratory syndrome coronavirus, Severe acute respiratory syndrome, COVID-20

Each new copy of a virus contains tiny copying errors or variations in its genome which is what is referred to as a variant.

Key Points: 
  • Each new copy of a virus contains tiny copying errors or variations in its genome which is what is referred to as a variant.
  • Novi is the only hand-held, portable, battery powered device with built-in redundancy, delivering the most accurate results of any testing device.
  • A US government SARS-CoV-2 Interagency Group (SIG) developed Variant Classifications that defines three classes of SARS-CoV-2 variants.
  • Bacter Scientific does not assume the obligation to update any forward-looking statement, except as required by applicable law.

ENZO BIOCHEM RECEIVES FDA EMERGENCY USE AUTHORIZATION FOR RAPID EXTRACTION METHOD ON PROPRIETARY TEST SYSTEM FOR DETECTION OF CORONAVIRUS SARS-CoV-2

Retrieved on: 
Tuesday, July 20, 2021
Coronaviridae, Sarbecovirus, Zoonoses, Severe acute respiratory syndrome, Severe acute respiratory syndrome coronavirus, Assay, COVID-19, DiaSorin, Curative

The rapid extraction method can be used on platforms including Enzos proprietary GENFLEX automated high-throughput platform, Qiagens QIAsymphony SP lower-throughput platform and Enzos manual workflow.

Key Points: 
  • The rapid extraction method can be used on platforms including Enzos proprietary GENFLEX automated high-throughput platform, Qiagens QIAsymphony SP lower-throughput platform and Enzos manual workflow.
  • The AMPIPROBE SARS-Cov-2 Test System includes three components: sample collection, AMPIXTRACT SARS-CoV-2 Extraction Kit for sample processing, and AMPIPROBE SARS-CoV-2 Assay Kit for detection and analysis.
  • We are positioned to support rapid scale up and advance the new solutions in molecular testing that can address major challenges like COVID.
  • The Company disclaims any obligations to update any forward-looking statement as a result of developments occurring after the date of this release.

Immunome Antibody Cocktail (IMM-BCP-01) Neutralizes the SARS-CoV-2 Delta Variant in Pre-clinical Testing

Retrieved on: 
Tuesday, July 20, 2021
Biotechnology, Pharmaceutical, Health, Clinical trials, Coronaviridae, Zoonoses, Variants of SARS-CoV-2, Antiviral drugs, COVID-19 pandemic in Russia, Severe acute respiratory syndrome coronavirus 2, COVID-19, SARS-CoV-2 Delta variant, Immunome, Coronavir

Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, announced today that its three-antibody cocktail (IMM-BCP-01) has demonstrated potent neutralizing activity against the SARS-CoV-2 Delta variant in pre-clinical pseudovirus testing.

Key Points: 
  • Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, announced today that its three-antibody cocktail (IMM-BCP-01) has demonstrated potent neutralizing activity against the SARS-CoV-2 Delta variant in pre-clinical pseudovirus testing.
  • Furthermore, IMM-BCP-01 showed in-vitro activity via non-neutralizing mechanisms, such as complement fixation, which Immunome expects will enable viral clearance.
  • IMM-BCP-01s ability to maintain neutralizing activity against emerging SARS-CoV-2 variants, including the Delta variant, potentially positions our drug candidate as a long-term solution to the changing threat posed by COVID-19.
  • Currently, the delta variant accounts for a majority of coronavirus cases in the United States.

Meissa Announces Preclinical Data on Intranasal COVID-19 Vaccine Showing Protection from SARS-CoV-2 Challenge after a Single Dose

Retrieved on: 
Tuesday, July 20, 2021
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Infectious diseases, Clinical trials, Clinical trials, COVID-19 vaccines, Coronaviridae, RNA vaccines, Medicine, Health sciences, COVID-19 vaccine, Medical research, Severe acute respiratory syndrome coronavirus, Rapid Deployment Vaccine Collaborative, ZF2001

The data demonstrate that a single adjuvant-free dose of MV-014-212 provided equivalent protection against SARS-CoV-2 challenge compared to reported efficacy in NHP models of currently authorized vaccines.

Key Points: 
  • The data demonstrate that a single adjuvant-free dose of MV-014-212 provided equivalent protection against SARS-CoV-2 challenge compared to reported efficacy in NHP models of currently authorized vaccines.
  • The data suggest a single, adjuvant-free, needle-free intranasal dose of MV-014-212 may provide broad immunity to protect against infection by SARS-CoV-2 and its variants.
  • In NHPs, Meissas intranasal COVID-19 vaccine generated both mucosal and systemic antibodies and was highly protective against wild-type SARS-CoV-2 challenge.
  • We believe Meissas intranasal COVID-19 vaccine has the potential to be an important part of the endgame solution to contain SARS-CoV-2.

US COVID-19 Surveillance Needs an Urgent Boost, Says AHF

Retrieved on: 
Tuesday, July 20, 2021
Infectious diseases, Genetics, Public policy, Government, Healthcare reform, White House, Federal Government, Health, State, Local, Public policy, Other Policy Issues, Coronaviridae, Sarbecovirus, Zoonoses, Bat virome, Severe acute respiratory syndrome, Severe acute respiratory syndrome coronavirus, Variant, SARS-CoV-2 Delta variant

New cases are up 129.3% from their lowest point on June 20, 2021, according to CDCs data on a seven-day moving average of recorded cases.

Key Points: 
  • New cases are up 129.3% from their lowest point on June 20, 2021, according to CDCs data on a seven-day moving average of recorded cases.
  • The most common strain of the virus is the highly infectious Delta variant, but the US is falling behind other developed countries in tracking and identifying new strains.
  • SARS-CoV-2 is highly prone to genetic variation as it replicates and spreads across different populations.
  • To learn more about AHF, please visit our website: www.aidshealth.org , find us on Facebook: www.facebook.com/aidshealth and follow us on Twitter: @aidshealthcare and Instagram: @aidshealthcare
    View source version on businesswire.com: https://www.businesswire.com/news/home/20210719005833/en/

EPA Adds Maryland, Nevada, Pennsylvania and Texas to Existing Public Health Emergency Exemption for Grignard Pure™ as Only Antiviral Air Treatment for Use Against COVID-19

Retrieved on: 
Monday, July 19, 2021
White House, Federal Government, Public policy, Government, Health, Infectious diseases, Environment, General Health, Coronaviridae, Sarbecovirus, Severe acute respiratory syndrome

The additional Emergency Exemptions are approved for Maryland, Nevada, Pennsylvania and Texas, joining Georgia and Tennessee, which were approved on January 14, 2021.

Key Points: 
  • The additional Emergency Exemptions are approved for Maryland, Nevada, Pennsylvania and Texas, joining Georgia and Tennessee, which were approved on January 14, 2021.
  • Grignard Pure is the first and only EPA-approved antimicrobial air treatment solution designed to significantly reduce the viral load of the SARS-CoV-2 virus in the air, where transmission is most likely.
  • The EPA undertook a thorough review of the products health, safety, and efficacy performance, and confirmed Grignard Pures effectiveness in killing more than 98% of the SARS-CoV-2 virus.
  • To learn more about Grignard Pure, including access to safety and efficacy reports, visit GrignardPure.com or call 1 (855) 642-PURE (7873).

Hologic Obtains European CE Mark for Use of Saliva Samples with COVID-19 Test

Retrieved on: 
Wednesday, July 14, 2021
Science, Other Science, Biotechnology, General Health, Health, Medical devices, Infectious diseases, Genetics, Coronaviridae, Sarbecovirus, Zoonoses, Medical tests, Medical genetics, Bat virome, Hologic, Severe acute respiratory syndrome coronavirus, Molecular diagnostics, Severe acute respiratory syndrome, COVID-19

Hologic, Inc. (Nasdaq: HOLX) has obtained a CE Mark for the use of saliva samples with the Aptima SARS-CoV-2 assay in Europe.

Key Points: 
  • Hologic, Inc. (Nasdaq: HOLX) has obtained a CE Mark for the use of saliva samples with the Aptima SARS-CoV-2 assay in Europe.
  • The Aptima SARS-CoV-2 test is a molecular diagnostic assay that detects the genetic material of the pathogen causing COVID-19.
  • This new CE Mark demonstrates our commitment to providing European consumers and healthcare providers as many options as possible to manage the ongoing pandemic, said Jan Verstreken, Hologics group president, International.
  • Hologic, The Science of Sure, Aptima, and Panther are registered trademarks of Hologic, Inc. in the United States and/or other countries.

Seegene Introduces New SARS-CoV-2 Variants Detection Test That Can Screen Six Virus Variants Including the Delta and Delta Plus

Retrieved on: 
Tuesday, July 13, 2021
Coronaviridae, Variants of SARS-CoV-2, COVID-19, Sarbecovirus, Zoonoses, Severe acute respiratory syndrome coronavirus 2, Severe acute respiratory syndrome, SARS-CoV-2 lineage B.1.617, SARS-CoV-2 Zeta variant

Seegene launches new multiplex PCR test capable of screening six SARS-CoV-2 variants including the Delta and Delta Plus variants attributable for a recent surge in global COVID-19 cases.

Key Points: 
  • Seegene launches new multiplex PCR test capable of screening six SARS-CoV-2 variants including the Delta and Delta Plus variants attributable for a recent surge in global COVID-19 cases.
  • In a single reaction, the variants diagnostic kit identifies a total of six COVID-19 variants that are known to be originated from India such as Delta, Delta Plus, and Kappa, and Gamma(Brazil), Beta(South Africa), and Epsilon(California).
  • Seegene also said that it has successfully developed a research-use-only diagnostic tests, 'Allplex SARS-CoV-2/P681R Assay,' to precisely target the Delta and Delta Plus variants.
  • According to Seegene, the combination use of its two assays including 'Allplex SARS-CoV-2 Variants II Assay' and the 'Allplex SARS-CoV-2 Variants I Assay' can screen almost all existing COVID-19 variants.